Aurinia Pharmaceuticals (AUPH) Accumulated Expenses (2023 - 2026)

Aurinia Pharmaceuticals' Accumulated Expenses history runs 4 years deep, the most recent figure standing at $58.2 million for Q1 2026.

• Quarterly Accumulated Expenses rose 37.41% year-over-year to $58.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $58.2 million (up 37.41% YoY) and the FY2025 annual result came in at $66.6 million, up 2.54% from the prior year.
• Accumulated Expenses was $58.2 million for Q1 2026 at Aurinia Pharmaceuticals, down from $66.6 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $66.6 million in Q4 2025 and bottomed at $42.4 million in Q1 2025.
• A 4-year average of $54.5 million and a median of $50.1 million in 2023 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2025 — Accumulated Expenses increased 2.54% — and 2026, when it soared 37.41%.
• Aurinia Pharmaceuticals' Accumulated Expenses stood at $50.1 million in 2023, then grew by 29.78% to $65.0 million in 2024, then rose by 2.54% to $66.6 million in 2025, then retreated by 12.65% to $58.2 million in 2026.
• Business Quant data shows AUPH's Accumulated Expenses at $58.2 million in Q1 2026, $66.6 million in Q4 2025, and $49.5 million in Q3 2025.